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Abstract 
 
Tenofovir disoproxil fumarate (TDF) and lopinavir/ritonavir (LPV/r) can cause renal impairment with 
this combination co-administered during second-line combination antiretroviral therapy (cART) 
potentially associated with greater risk of nephrotoxicity. Objective: Assess effects of second-line 
cART on renal function. Methods: Retrospective longitudinal study in patients receiving cART. 
Results: 71 patients received TDF, zidovudine or stavudine, each combined with 3TC/NVP or 3TC/ 
EFV. Before second-line cART, 46.5% had abnormal kidney function. First-line cART had no 
relationship with  calculated creatinine clearance (CrCl). During second-line cART, more males than 
females had abnormal renal function and more females experienced increases in CrCl. Calculated 
CrCl during second-line cART related strongly with CrCl during first-line cART; time spent on cART 
weak relationship with CrCl. Conclusion:  Patients on first-line cART for several years without renal 
impairment may experience new onset impairment during cART. Patients with pre-existing renal 
impairment just before switching to second-line cART may experience a further decline.  
 
Key words: Namibia, renal function, creatinine clearance, combination antiretroviral therapy, drug 
utilisation study 
 
Introduction 
 
Initiatives supporting the availability and accessibility of cART have significantly reduced morbidity 
and mortality of people infected with the HIV in resource limited settings [1]. Despite the positive 
impact on patient survival, antiretrovirals (ARVs) can cause adverse drug reactions (ADRs). Tenofovir 
Disoproxil Fumarate (TDF) is known to cause acute and chronic renal impairment [2]. Similarly, 
lopinavir /ritonavir (LPV/r) , is associated with renal ADRs [3, 4]. The preferred first-line cART regimen 
is TDF/lamivudine (3TC)/Nevirapine (NVP) or Efavirenz (EFV). At the time of writing this paper, LPV/r 
is the only PI available for second-line cART in the public sector in Namibia, and is co-administered 
with TDF, 3TC and AZT [5]. Since TDF and LPV/r are associated with nephrotoxicity, their co-
administration poses a higher risk for renal impairment [6, 7]. It should be noted that the risk of renal 
impairment may be influenced by gender, because of the hormonal differences between males and 
females [8]. 1DPLELD¶VDQGcART guidelines recommended the calculation of CrCl every 
six months for all patients receiving TDF-containing cART. The calculated CrCl provides evidence on 
ZKLFK7')¶VGRVLQJLQWHUYDOVDUHHLWKHUSURORQJHGRUXQFKDQJHG[9]. Since Namibia is an ethnically 
diverse nation, the Cockcroft-Gault (C-G) method is preferred because it does not gUDGHWKHSDWLHQWV¶
CrCl based on ethnicity.  
 
TDF undergoes renal elimination through a combination of glomerular filtration and active tubular 
secretion. The efflux of TDF from the tubular cells into the filtrate is mediated by Adenosine-¶-
Triphosphate Binding Cassette (ABC) C4 and Multi-Drug Resistance Protein-4 (MRP-4) and MRP-7 
[10]. By inhibition of the mitochondrial DNA-polymerase gamma, TDF impairs the functioning of 
energy dependent transporters [11,12]. Ritonavir (RTV) has a minimal effect on MRP-4. Hence, the 
effects of ritonavir seem not to increase renal exposure to TDF [13]. Nevertheless, the co-
administration of TDF with RTV is associated with increased risk of renal impairment, and it is 
believed that the inhibition of the permeation glycoprotein ± MRP-4 ± by RTV results in increased 
exposure of TDF to the proximal tubular cells [14,15].  
 
In a letter to the editors of JAIDS1, Sorli et al (2008) said that the prevalence of kidney impairment 
amongst HIV infected patients receiving cART was 3.5% - 4.7%, and 15.5% among the black 
population [16]. Renal impairment is a cause for concern as it is an independent risk factor for 
cardiovascular disease (CVD) and is on the rise among HIV infected patients [17,18].  
 
The co-administration of TDF and LPV/r and its effects on renal function in HIV-infected patients in 
Namibia has not been elucidated. As such, it was not known whether the risk of reduced renal 
function during the administration of cART was influenced by gender and/ or the length of time spent 
on second-line therapy. In this paper we present the outcomes, namely: decline or improvement, and 
give plausible explanations of these outcomes in HIV-infected patients who were receiving second-
line cART to provide future guidance to decision makers. 
 
Methods 
 
Study design 
This was a retrospective longitudinal study that employed a mixture of descriptive and analytical 
statistics. 
 
Study setting 
The study was implemented at the HIV clinic at the Katutura Intermediate Hospital (KIH).  
 
Study population 
A list of patients on second-line cART was generated from the electronic Dispensing Tool (EDT - The 
EDT is a computerised database that stores cART dispensing records for all patients receiving ART in 
the public sector in Namibia. The EDT provides the cART start date; all the medicine regimens the 
patient has received; any drug substitutions that were made, and the dates for any changes). Using 
key identifiers in the EDT, we accessed the patient care booklets (PCB) from which we extracted the 
data (PCBs are paper-based patient files which contain data on their medical, drug, and laboratory 
histories ± including SeCr, and notes on progression of therapy).  We acknowledge that changes in 
the frequency of clinic visits is one of the main interventions made to decongest HIV clinics, which 
happens in the majority of patients who are adherent to their ART and are responding well to the 
therapy. 
 
Consistent wLWK1DPLELD¶V$57JXLGHOLQHV we calculated the CrCl. Similar to Bygrave HWDO¶V (2011) 
study on TDF and its effect on renal function, we categorised patients in their respective grades of 
renal function based on their CrCl as follows [9]. 
x Definitions of renal function: The categories of renal function into which the patients were 
classified are shown in Table 1.  
x Any CrCl below 90ml/min was categorised as abnormal 
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Table 1: Renal function categories, based on CG calculation 
 
Grade CrCl  
I (Normal)   
II (Mild)  60 ² <90 
III (Moderate)  30 ² <60 
IV (Severe)  <30 
 
x Renal function was considered to have declined if the last CrCl during second-line cART was 
OHVVWKDQWKHODVW&U&O during first-line therapy. In addition, when the SeCr was noted to 
KDYHLQFUHDVHGE\GXULQJVHFRQG-line cART, renal function was considered to have 
declined. A drop in CrCl from 20 - <25% was referred to as a reduction renal function 
x Renal function was considered to have improved if the last CrCl during second-line treatment 
was PRUHWKDQWKHODVW&U&OGXULQJILUVW-line treatment. When the SeCr was noted to 
KDYHGHFUHDVHGE\GXULQJVHFond-line treatment, coupled with a change of CrCl from 
abnormal to normal the renal function (even though the CrCl was <25%), this was considered 
to have improved 
 
.  
Ethics 
Anonymity of the patients and confidentiality with the data was assured. The study was approved first 
by the School of Pharmacy, Faculty of Health Sciences: University of Namibia, then by the Ministry of 
Health and Social Services (MoHSS), Namibia.  
 
Statistical analysis 
Frequency data was described and presented in tables. We used the Binomial Distribution test to 
assess whether the declinHLQUHQDOIXQFWLRQWKDWLV&U&OZDVVWDWLVWLFDOO\VLJQLILFDQW:HXVHG
0F1HPDU¶VWHVWWRDVVHVVWKHFKDQJHVLQ&U&OEDVHGRQDQ\UHGXFWLRQRULQFUHDVHPOPLQWe 
used the Chi-square Test to determine if there was a difference between the number of males and 
females with abnormal renal function at the end of first-line cART, and during second-line treatment; 
and to assess the possible relationship between the first-line cART regimens and renal function. We 
used scatter plots and Spearman Correlation Co-efficient to visualise and explain the relationships 
between CrCl values; CrCl and patient age; and CrCl and time spent on second-line therapy. We 
used Spearman Correlation Co-efficient to explain the strength of relationships between the above 
mentioned variables. The confidence level was set at 95% and the statistical significance at a p-value 
of <0.05. 
 
Findings 
 
Frequency: Demographics and ART data 
A total of 71 patients who were receiving second-line ART at KIH were included in the study. Female 
patients made up 57.7% of the population.  The average age of the population at the time of switching 
from first-line to second-line cART was 42 years. The first-line ART regimen they received  was 
TDF/3TC, AZT/3TC, and D4T/3TC each combined with either NVP or EFV. These patients spent an 
average of 5.2 years on first line cART. At the time of data collection, they had spent an average of 
1.8 years on second-line cART (Table 2). All patients received TDF/3TC/AZT/LPV/r as the second-
line regimen (Table 2), which was prescribed following evidence of immunologic, virologic, and clinical 
failure. Overall, Table 2 documents the total number of patients, the number per regimen, and the 
time period spent on first- and second- line ART by gender.  
 
 
  
Table 2: Demographics and ART regimen data distributed by gender 
 
  All Females  Males 
Total number of patients 71(100%) 41(57.7%) 30 (42.3%) 
Average age of the patients (years) 42 (26 - 55) 41 (29-55) 43 (26-51) 
First line ART Regimens     
 TDF/3TC/EFV 18(25.4%) 11 (15.4%) 7 (10.0%) 
TDF/3TC/NVP 25 (35.2%) 13 (18.3%) 12 (16.9%) 
TDF/FTC/NVP 1 (1.4%) 1 (1.4%) - 
AZT/3TC/EFV 2 (2.8%) 1 (1.4%) 1 (1.4%) 
AZT/3TC/NVP 14 (19.7%) 9 (12.7%) 5 (7.0%) 
D4T/3TC/EFV 5 (7.0%) 1 (1.4%) 4 (5.6%) 
D4T/3TC/NVP 6 (8.5%) 5 (7.0%) 1 (1.4%) 
Second line ART Regimen     
 TDF/3TC/AZT/LPV-r 71 41 30 
Mean years on 1st line ART (range) 5.2 (1.2 - 10) 5.2 (1.2 - 9.9) 5.3 (1.3 - 10) 
Mean years on 2nd line ART (ranget) 1.8 (0.7 - 2.6) 1.8(0.7 - 2.6) 1.7 (0.7 - 2.6) 
 
Findings related to kidney function  
 
SeCr tests 
At the time of data collection, the patients had undergone two to five SeCr tests (Table 3).  
 
Table 3: Number of SeCr results per-patient and outcomes on SeCr and CrCl 
 
 
 
 
 
 
CrCl results before second-line ART 
Before initiation of second-line ART, almost half (46.5%, n=33) of the patients had abnormal renal 
function (that is <90ml/ min). Females and males accounted for 25.4% and 21.1%, respectively (Table 
4). Overall, Table 4 documents the total number (percentage) of patients with normal kidney function 
at the end of first-line cART, which was slightly higher than the number with abnormal renal function. 
There was no statistically significant difference between females and males in the numbers of patients 
with abnormal renal function (p=0.61), (Table 4).  
  
Period 
Number of 
SeCr tests  per patient Patients 
Before and after switching to 
second-line cART 
2 20 (28.2%) 
3 28 (39.4%) 
4 18 (25.4%) 
5 5 (7.0%) 
Table 4: Grades of renal function at the end of first-line ART 
 
Grade of Renal Function 
Number of Patients 
All Female Male 
*UDGH,POPLQ 38(53.5%) 23(32.4%) 15(21.1%) 
Grade II  (60 ² <90ml/min) 32 (45.1%) 18 (25.4%) 14 (19.7%) 
Grade III  (30 ² <60 ml/min) 1(1.4%) _ 1(1.4%) 
Grade IV  ( <30 ml/min) _ _ _ 
 
CrCl results during second-line ART 
During second-line cART, the proportion of patients with abnormal renal function was not different 
from that during first line cART (46.5%, n=33). However, there were more males than females with 
abnormal renal function (p=0.01) (Table 5).  The numbers (percentages) of patients who experienced 
decline, reduction, or improvement in CrCl and SeCr are shown in tables 6a (Tables 6b and 6c are 
extracts from table 6a). Overall, eight RIWKHSDWLHQWVZLWKGHFOLQHLQ&U&ODOVRPRYHGIURPJUDGH
I to grade II of the renal function grading system (Table 6). Four experienced a worsening of grade II. 
Of the patients who experienced a GHFOLQHLQ6H&UPOPLQWZRKDGDFKDQJHIURPDEQRUPDOUHQDO
function (78 and 79ml/min) to normal renal function (96ml/min and 95ml/min, respectively). Four of 
them had normal renal function. 
 
Based on the binomial distribution test, DVLJQLILFDQWGHFOLQHLQ&U&ODVRSSRVHGWR
LPSURYHPHQWUHGXFWLRQLQ6H&UFRXSOHGZLWKDFKDQJHIURPDEQRUPDOWRQRUPDO&U&OZDV
observed (p = 0.000). Similarly,  aQDQDO\VLVE\0F1HPDU¶VWHVWbased on the fact that CrCl dropped 
E\LQSDWLHQWVDQGQRQHKDGDQLQFUHPHQWLQ&U&O, we found that there was a 
significant change in the number of patients who changed from normal to abnormal renal function (p 
=0.000). 
 
Table 5: Grades of renal function during second line ART 
 
Grade of Renal Function 
Number of Patients 
All Female Male 
*UDGH,POPLQ 38(53.5%) 27(38.0%) 11(15.5%) 
Grade II (60 ² <90ml/min) 31(43.7%) 13(18.3%) 18(25.4%) 
Grade III (30 - <60 ml/min) 2(2.8%) 1(1.4%) 1(1.4%) 
Grade IV  (² <30 ml/min) _ _ _ 
 
  
Table 6a: Numbers of patients with changes in renal function based on CrCl and SeCr  
 
 Number (%) of Patients  
 CrCl SeCr  
Percentage 
reduction in CrCl    
Percentage increase in 
SeCr 
 12 (16.9%) 3 (4.2%)   
10 - <20% 23 (32.4%) 11 (15.5%) 10 - <20% 
<10% 13 (18.3%) 22 (31.0%) <10% 
Sub-totals 59 (83.1%) 39(54.9%)  
Percentage increase 
in CrCl    
Percentage decrease in 
SeCr 
 - 6 (8.5%)  
20 - <25% 3 (4.2%) 3 (4.2%) 20 - <25% 
10 - <20% 3 (4.2%) 9 (12.7%) 10 - <20% 
<10% 6 (8.5%) 14 (19.7%) <10% 
Sub-totals 12 (16.9%) 32(45.1%)  
 
Table 6b: Gender-based breakdown of CrCl outcomes of renal function during second-line ART  
 
Renal function status 
Number of Patients 
All Females Males 
'HFOLQHLQ&U&O 12 (16.9%) 4 (5.6%) 8 (11.3%) 
Decline or improvement in CrCl  <25%  59 (83.1%) 37 (52.1%) 22 (30.9%) 
,PSURYHPHQWLQ&U&O - - - 
 
Table 6c: Gender-based breakdown of SeCr outcomes of renal function during second-line ART 
 
Renal function status 
Number of Patients 
All Females Males 
,QFUHDVHLQ6H&U 3 (4.2%) 1 (1.4%) 2 (2.8%) 
Increase or decrease in SeCr  <25% 62 (87.3%) 36 (50.7%) 26 (36.6%) 
'HFUHDVHLQ6H&U 6 (8.5%) 4 (5.6%) 2 (2.8%) 
 
 
Effect of first-line ART regimens on CrCl 
There was no difference between TDF-based and TDF-sparing first-line ART regimen, on the CrCl 
(95% CI: 102 [94-111] vs. 95 [87-102] ml/min; p=0.78). Furthermore, we observed that the type of 
first-line (TDF-based vs. TDF-sparing) regimen did not influence the CrCl during second-line ART 
(95%CI: 105 [96-114] vs. 96 [87-104] ml/min; P=0.90).  
 
Relationships between variables 
x There was a strong positive relationship between the CrCl before second line therapy and the 
CrCl during second line cART (r=0.8; p=0.000) 
x There was a mild-strength negative relationship between patient age and CrCl during first line 
cART (r=0.3) 
x During second-line cART, the relationship was similar to that observed during first-line ART; 
however, it was slightly stronger (r=0.4) 
x There was no covariance between the time spent on cART and CrCl during second- line cART 
treatment (r=0.1, p>0.05), 
 
Overall, CrCl did not co-vary with time spent on first line or second line cART (Figures 1 and 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Discussion 
 
Renal Function during First-line cART 
In our study, the proportion of patients with renal impairment during first-line treatment was large, but 
this observation was not interpretable as an increased incidence of ARV-induced renal disease for a 
number of reasons. Firstly, the patients had experienced treatment failure, and were therefore not 
representative of the population of patients normally receiving first-line treatment.  Secondly, some 
patients may have experienced HIV-associated renal impairment as their viral load was high. Thirdly, 
pre-existing renal impairment at the time of cART initiation could have been a contributing factor for 
renal impairment before switching to second-line treatment.  Lastly, because of lack of data 
concerning co-morbidities, other potential causes of renal impairment could not be ruled out.  
 
Decreased Renal Function during Second-line cART 
Some patients, who had normal renal function before switching, experienced new onset decline in 
CrCl. Others seemed to experience a further reduction in CrCl.  A large multinational cohort study ± 
The D:A:D2 Study ± had shown that renal impairment progresses with increasing time of exposure to 
TDF [19].  However, due to the great inter-patient variability in this study, the length of exposure to 
TDF-containing cART was weakly associated with the decline in CrCl (r=0.1). Since the population we 
studied was small and different in structure to that of the D:A:D study, we do not believe our findings 
are different to those of the D:A:D study. Advancing age is a known risk factor for reduced renal 
function [20].  Our findings are in agreement with this physiological norm, although the strength of the 
relationship between age and CrCl during second-line cART was moderate (r=0.4). A low CrCl before 
initiation of cART is another risk factor for further decline in renal function, especially if patients are 
exposed to nephrotoxic agents [21]. For that reason, the Namibian cART guidelines recommend the 
avoidance of TDF in patients with a CrCl below <60ml/min [5,22]. In a study by Gallant and Moore 
(2009), TDF-based first-line treatments were shown to cause an initial decline in renal function which 
lasted around 180 days [23]. A similar result was shown in a study by Miguel et al. (2008) [24]. As 
such, patients with a CrCl <60ml/min may experience a clinically significant regression in their renal 
IXQFWLRQQHFHVVLWDWLQJ7')¶VZLWKGUDZDO. The perfect positive co-variation (r=0.9) of the baseline with 
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Figure 2: Variation of CrCl with time 
spent on 2nd line ART
the outcome CrCl observed in this study is in agreement with this rule. However, the few cases of 
new-onset declines in, and cases of normalisation of renal function, are diversions to this rule.  
 
This information calls for further observation and assessment of the safety of recommended second-
line treatments in Namibia. On the other hand, the observed decline in renal function may have 
stabilised at stage II of renal function, meaning that further declines are not expected. The 
pharmacodynamic interaction between TDF and LPV/r partly explains the pathological basis of new-
onset and further declines in renal function.  
 
Improvement of renal function /CrCl 
Some patients who had abnormal renal function at the end of first line therapy experienced 
improvement. Some experienced a rise in CrCl <25%.   The patients whose renal function improved 
&U&OLQFUHDVHGE\DQGWKRVHZKRVH&U&OLQFUHDVHGE\- <25% -, had received first-line 
treatment for a mean period of 3.2 years. Consequently, ARV-associated nephropathy is worth 
suspecting.  However, the increment in CrCl that occurred during the administration of two 
nephrotoxic agents ± TDF and LPV/r - leaves room for one possible explanation, i.e.  the renal 
impairment that occurred in this particular group of patients was HIV-associated due to treatment 
failure.   
 
Renal impairment in the setting of treatment failure can be judged to be induced by TDF, but this may 
not always be the case. Consequently, detection of renal impairment in patients receiving TDF-
containing cART can falsely increase pharmacovigilance-based reports of TDF-associated renal 
impairment, and the time of occurrence and the other clinical events at that particular time need to be 
taken into account before TDF is assumed to be the cause of the observed renal impairment. One key 
observation is that the majority of patients who were observed to have experienced renal impairment 
during second-OLQHF$57Q KDGD&U&O!POPLQWKHWKUHVKROGEHORZZKLFK7')¶VGRVDJHLV
advised [25].   
  
 
Limitations 
2XUVWXG\KDGDQXPEHURIOLPLWDWLRQV)LUVWO\ZHFDWHJRULVHGVRPHSDWLHQWV¶UHQDOIXQFWLRQRQWKH
basis of one or two SeCr results, yet SeCr levels are known to vary in the same patient due to factors 
other than renal impairment, e.g., the factors associated with an increase in SeCr include an increase 
in muscle mass, some co-administered drugs such as trimethoprim and cimetidine, and the ingestion 
of cooked meats. Factors associated with a decrease in SeCr include muscle wasting, amputation, 
and a vegetarian diet [26]. Consequently, misclassification of renal function could not be ruled out 
from our findings. Nevertheless, the majority of patients we observed to have experienced a decline in 
their renal function (10 out of 12) had more than two SeCr tests during second-line treatment: five had 
three, four had four, and one had five tests, and these tests were carried out between 0.8 ± 2.2 years 
-  these patients had spent a mean of 1.7 (1.3-2.2) years on second line cART. The Namibia cART 
JXLGHOLQHVWKDWZHUHLQIRUFHGXULQJWKLVVWXG\UHFRPPHQGHGWKDWSDWLHQWV¶UHQDOIXQFWLRQVKRXOGEH
assessed every six months. Based on the number of SeCr tests carried out for these patients, the 
Namibia cART guidelines were generally complied with.  However in light of the fact that there were 
unmeasured confounders, we advise that there is caution around these findings.  The same caution, 
for the same reasons, should be exercised when interpreting the findings for patients who seemed to 
experience an increase in CrCl. Secondly, our study only had a relatively small number of patients. 
This was due to the fact that our facility only had relatively few patients receiving second-line 
treatment. Thirdly, we acknowledge that we did not abstract data on renal function pre- first-line, and 
this missing data led to speculations about the findings at the end of first-line, even though these 
speculations were clinically sound. Fourthly, there was variation in the length of time between the last 
measurement of SeCr and the switch date. It could have been that the CrCl just before switching was 
lower or even higher than what we considered as baseline. However, the fact that renal function was 
observed to improve during second-line treatment appears to addresses the concern for low CrCl, but 
for high CrCl patients this would mean no change in renal function. Overall though we believe our 
findings are valid and provide direction to the authorities in Namibia. 
 
Conclusion 
 
Exposure to second-line ART is likely to result in two major outcomes with respect to renal function, 
namely: decline or improvement. Our findings showed that patients who have received first-line 
regimens for several years without renal impairment may experience new onset renal impairment 
during second-line treatments containing TDF, 3TC, AZT and LPV/r. Our findings also showed that 
patients who were switched to second-line cART with pre-existing renal impairment may experience a 
further decline in renal function. For these two categories of patients ± new onset and worsening renal 
impairment - the decline in renal function was likely drug induced.  To identify the causative agent is 
challenging as the renal impairment may be caused by TDF alone or a combination of TDF and 
LPV/r, or RTV alone.  
 
Renal impairment that co-occurs with failure of first-line treatment may be HIV- rather than ARV - 
related. Our study also showed that the outcome of renal function during second-line treatment was 
instrumental in determining whether the former or the latter was the cause of renal impairment during 
first-line therapy. If the cause was HIV-related, resolution of renal impairment would occur following 
the use of potent second-line regimens. When a further decline in renal function occurs during the use 
of potent second-line regimens, the suspicion for it being ARV-induced is stronger, whether or not 
TDF was part of the first-line regimen.  
 
Our findings showed that male patients were more at risk of renal impairment than female patients 
when exposed to second-line regimens containing TDF and LPV/r. However, notice should be given 
to the small sample size and to the relatively short time spent on second-line regimens among our 
patient population. 
  
Pre- second-line CrCl could be a predictor of the CrCl during second-line treatments; however, new 
onset renal impairment and improvements in renal function cannot be ruled out. Careful follow up with 
renal function tests for all patients receiving second-line treatment is clinically valuable.  We could not 
conclude though on the possible future outcomes of renal function for those patients whose renal 
function was normal before and during second-line cART.  
 
Since renal impairment increases DSDWLHQW¶V risk of CVD, further studies need to be undertaken to 
estimate the prevalence of renal impairment during first- and second- line cART in Namibia. This 
includes patients of both sexes given the low numbers of female patients in most studies amongst 
Western populations. The estimated prevalence will be useful for justification of possible interventions 
such as the replacement of TDF with TAF in resource limited settings, as the latter may be safer, but 
possibly more costly. Such information could also be used for the design of measures to protect 
patients against CVD.  
 
Key Messages 
x Patients who received TDF-containing cART during first-line treatment and do not develop renal 
impairment, may develop renal impairment during second-line cART. Continued monitoring of 
renal function is critical. 
x Concurrent renal impairment with cART failure could result in over reporting of TDF-related renal 
reactions, JLYLQJDZURQJSHUFHSWLRQRI7')¶VVDIHW\. Consequently, it is advisable for health care 
workers to report the incident as TDF-related only if renal impairment persists or declines further 
during the use of a potent second-line regimens. 
x The presence of renal impairment during the use of TDF/3TC/EFV or NVP, does not 
FRQWUDLQGLFDWHWKHSUHVFULSWLRQRI7')7&$=7/39UEXWWKHSDWLHQWV¶UHQDOIXQFWLRQVKRXOGEH
monitored regularly   
x HIV infected men are more susceptible to renal impairment associated with TDF/3TC/AZT/LPV/r 
than women. 
x A larger and robust study is required to assess renal function in first- and second- line patient 
groups 
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